leisure time -WSS

leisure time

author：focus 2025-10-02 23:30:24 - browse：65872

Transparent plastic divider on the reception desk in the hospital admission department with red lettering emergency. — Adobe

QuidelOrtho has recalled nearly 8,000 potentially faulty blood tests meant to help doctors quickly determine whether a patient is having a heart attack.

The tests inaccurately showed low levels of troponin, a protein that indicates damage to the heart. A false negative could lead doctors to mistakenly conclude their patient is not having a heart attack, delaying diagnosis or treatment when time is of the essence.

The device maker, which also sells products like the QuickVue Covid-19 antigen test, sent letters to health systems in May telling them to immediately stop using the test. The Food and Drug Administration classified the recall as serious, because problems with the product could result in serious injury or death. QuidelOrtho has reported 41 complaints, but no injuries or deaths so far.

The tests, which use either a blood or plasma sample, promise to return results in under half an hour. They are used in emergency rooms to triage patients suspected of having a heart attack.

Related: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?

The FDA said the patients most at risk are those with zero or abnormal heart attack symptoms, for whom a diagnosis would be easy to miss without an accurate lab test.

The company advised using a different testing method to detect heart attacks. If none are available, doctors should be extra wary of the blood panel’s readings, perform multiple tests to confirm low troponin levels, and also reference data from EKGs and other imaging.

San Diego-based QuidelOrtho said the error is due to a “raw material issue” in its recall record. The issue caused the test to falsely pick up 30% less troponin than is present. The company did not respond to STAT’s request for more information on the error.

The test maker’s last serious recall was in 2021 for reports of false negatives from its Lyra PCR Covid-19 test when used with certain lab equipment. The notice impacted more than 18,000 test kits.

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： AI models in health care face new federal disclosure requirements

focus

WSS

Do digital therapeutics have a future in medicine?

A $475,000 price tag for a new cancer drug: crazy or meh?

Apple Vision Pro: A first look at health apps on the new VR headset

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

The woman behind the Dana Farber

General Catalyst, Summa Health deal will turn on physician buy

leisure time

leisure time

Related: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?

focus

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

A $475,000 price tag for a new cancer drug: crazy or meh?

The cancer drug shortage isn’t new — and neither are the solutions

Commercial surrogacy can be ethical, despite pope’s claims

Bright Health sells Medicare Advantage business to Molina

Some dementia cases could be undiagnosed liver disease

Medical records are filled with copy

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

knowledge

Pfizer plans to depart BIO

Congressmen charge Covid hearing ‘could have been an email’

Supreme Court wrestles with OxyContin maker's bankruptcy deal

AI models in health care face new federal disclosure requirements

The lessons of Aduhelm, an Alzheimer's drug that was not to be

Vertex non

focus

Wikipedia

focus

leisure time